Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

Abstract Background The growth factor progranulin has been implicated in numerous biological processes such as wound healing, inflammation and progressive tumorigenesis. Both its receptor sortilin are known to be highly expressed subgroups of breast cancer have associated with various clinical properties including tamoxifen resistance. Recent data further suggest that progranulin, via sortilin, drives stem cell propagation vitro increases metastasis formation an vivo xenograft model. In this retrospective biomarker analysis, we aimed determine whether tumor co-expression prognostic treatment predictive values for patients. Methods We explored how was established markers by analyzing a tissue microarray 560 randomized premenopausal patients receiving either 2 years or no adjuvant treatment, median follow-up time 28 years. Breast cancer-specific survival analyzed using Kaplan-Meier Cox Proportional Hazards regression models assess the value relation markers. Results Co-expression observed 20% samples. untreated patients, considerations could detailed separately from prediction high expressing subgroup significantly death multivariable analyses (HR=2.188, CI: 1.317–3.637, p =0.003) along size, grade lymph node positivity. When comparing treated ER? positive subgroup, not linked Conclusion Data is novel combination identifying malignant cancer. Importantly, subpopulation potentially targeted anti-sortilin based therapies.